Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > REGULATORY
REGULATORY
- 80% Rule for Combination Drugs Will Be Applied to Injectables, Topical Drugs: MHLW Proposal
December 5, 2011
- MHLW Announces Results of Reexamination for Iressa, Remicade as Category I
December 5, 2011
- PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
December 5, 2011
- Decision on Price Freeze for Medically Essential Drugs to Be Postponed
December 5, 2011
- Expert Subcommittee Approves 60% Pricing Rule for Some New Generics Only
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 3, 2011
- Two New Drugs Including Ranmark from Daiichi Sankyo Recommended at PAFSC's 2nd Committee
December 2, 2011
- SS Council Committees Approve Basic Plan on FY2012 Medical Fee Revision
December 2, 2011
- Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
- Discussion Items for Upcoming Reform of NHI Drug Pricing System (Expert Subcommittee on NHI Drug Pricing Affairs, Dec. 2)
December 2, 2011
- CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
- MHLW Announces Revision of Precautions for Anastrozole, Temozolomide
December 1, 2011
- CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
- Gov’t to Decide on Extension of Urgent Vaccination Project “as Soon as Possible”
November 30, 2011
- MLHW Announces Extension of Reexamination Period for Lonasen
November 29, 2011
- JAN Determined for 8 Drug Candidate Compounds
November 29, 2011
- Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
- MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
- MHLW Issues Notification on Modifications of Approval for Iressa
November 28, 2011
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…